CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment

Malinee Thanee, Watcharin Loilome, Anchalee Techasen, Eiji Sugihara, Shogo Okazaki, Shinya Abe, Shiho Ueda, Takashi Masuko, Nisana Namwat, Narong Khuntikeo, Attapol Titapun, Chawalit Pairojkul, Hideyuki Saya, Puangrat Yongvanit

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Expression of CD44, especially the variant isoforms (CD44v) of this major cancer stem cell marker, contributes to reactive oxygen species (ROS) defense through stabilizing xCT (a cystine–glutamate transporter) and promoting glutathione synthesis. This enhances cancer development and increases chemotherapy resistance. We investigate the role of CD44v in the regulation of the ROS defense system in cholangiocarcinoma (CCA). Immunohistochemical staining of CD44v and p38MAPK (a major ROS target) expression in Opisthorchis viverrini-induced hamster CCA tissues (at 60, 90, 120, and 180 days) reveals a decreased phospho-p38MAPK signal, whereas the CD44v signal was increased during bile duct transformation. Patients with CCA showed CD44v overexpression and negative-phospho-p38MAPK patients a significantly shorter survival rate than the low CD44v signal and positive-phospho-p38MAPK patients (P = 0.030). Knockdown of CD44 showed that xCT and glutathione levels were decreased, leading to a high level of ROS. We examined xCT-targeted CD44v cancer stem cell therapy using sulfasalazine. Glutathione decreased and ROS increased after the treatment, leading to inhibition of cell proliferation and induction of cell death. Thus, the accumulation of CD44v leads to the suppression of p38MAPK in transforming bile duct cells. The redox status regulation of CCA cells depends on the expression of CD44v to contribute the xCT function and is a link to the poor prognosis of patients. Thus, an xCT inhibitor could inhibit cell growth and activate cell death. This suggests that an xCT-targeting drug may improve CCA therapy by sensitization to the available drug (e.g. gemcitabine) by blocking the mechanism of the cell's ROS defensive system.

Original languageEnglish
Pages (from-to)991-1000
Number of pages10
JournalCancer Science
Volume107
Issue number7
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

Fasciola hepatica
Cholangiocarcinoma
Oxidation-Reduction
Reactive Oxygen Species
Neoplastic Stem Cells
gemcitabine
Bile Ducts
Glutathione
Cell Death
Therapeutics
Opisthorchis
Sulfasalazine
Drug Delivery Systems
Cell- and Tissue-Based Therapy
Cricetinae
Protein Isoforms
Survival Rate
Cell Proliferation
Staining and Labeling
Drug Therapy

Keywords

  • CD44v
  • cholangiocarcinoma
  • opisthorchiasis
  • redox status
  • sulfasalazine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thanee, M., Loilome, W., Techasen, A., Sugihara, E., Okazaki, S., Abe, S., ... Yongvanit, P. (2016). CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer Science, 107(7), 991-1000. https://doi.org/10.1111/cas.12967

CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma : A target for cholangiocarcinoma treatment. / Thanee, Malinee; Loilome, Watcharin; Techasen, Anchalee; Sugihara, Eiji; Okazaki, Shogo; Abe, Shinya; Ueda, Shiho; Masuko, Takashi; Namwat, Nisana; Khuntikeo, Narong; Titapun, Attapol; Pairojkul, Chawalit; Saya, Hideyuki; Yongvanit, Puangrat.

In: Cancer Science, Vol. 107, No. 7, 01.07.2016, p. 991-1000.

Research output: Contribution to journalArticle

Thanee, M, Loilome, W, Techasen, A, Sugihara, E, Okazaki, S, Abe, S, Ueda, S, Masuko, T, Namwat, N, Khuntikeo, N, Titapun, A, Pairojkul, C, Saya, H & Yongvanit, P 2016, 'CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment', Cancer Science, vol. 107, no. 7, pp. 991-1000. https://doi.org/10.1111/cas.12967
Thanee, Malinee ; Loilome, Watcharin ; Techasen, Anchalee ; Sugihara, Eiji ; Okazaki, Shogo ; Abe, Shinya ; Ueda, Shiho ; Masuko, Takashi ; Namwat, Nisana ; Khuntikeo, Narong ; Titapun, Attapol ; Pairojkul, Chawalit ; Saya, Hideyuki ; Yongvanit, Puangrat. / CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma : A target for cholangiocarcinoma treatment. In: Cancer Science. 2016 ; Vol. 107, No. 7. pp. 991-1000.
@article{0f052e25551c437f889df57fa7e733d0,
title = "CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment",
abstract = "Expression of CD44, especially the variant isoforms (CD44v) of this major cancer stem cell marker, contributes to reactive oxygen species (ROS) defense through stabilizing xCT (a cystine–glutamate transporter) and promoting glutathione synthesis. This enhances cancer development and increases chemotherapy resistance. We investigate the role of CD44v in the regulation of the ROS defense system in cholangiocarcinoma (CCA). Immunohistochemical staining of CD44v and p38MAPK (a major ROS target) expression in Opisthorchis viverrini-induced hamster CCA tissues (at 60, 90, 120, and 180 days) reveals a decreased phospho-p38MAPK signal, whereas the CD44v signal was increased during bile duct transformation. Patients with CCA showed CD44v overexpression and negative-phospho-p38MAPK patients a significantly shorter survival rate than the low CD44v signal and positive-phospho-p38MAPK patients (P = 0.030). Knockdown of CD44 showed that xCT and glutathione levels were decreased, leading to a high level of ROS. We examined xCT-targeted CD44v cancer stem cell therapy using sulfasalazine. Glutathione decreased and ROS increased after the treatment, leading to inhibition of cell proliferation and induction of cell death. Thus, the accumulation of CD44v leads to the suppression of p38MAPK in transforming bile duct cells. The redox status regulation of CCA cells depends on the expression of CD44v to contribute the xCT function and is a link to the poor prognosis of patients. Thus, an xCT inhibitor could inhibit cell growth and activate cell death. This suggests that an xCT-targeting drug may improve CCA therapy by sensitization to the available drug (e.g. gemcitabine) by blocking the mechanism of the cell's ROS defensive system.",
keywords = "CD44v, cholangiocarcinoma, opisthorchiasis, redox status, sulfasalazine",
author = "Malinee Thanee and Watcharin Loilome and Anchalee Techasen and Eiji Sugihara and Shogo Okazaki and Shinya Abe and Shiho Ueda and Takashi Masuko and Nisana Namwat and Narong Khuntikeo and Attapol Titapun and Chawalit Pairojkul and Hideyuki Saya and Puangrat Yongvanit",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/cas.12967",
language = "English",
volume = "107",
pages = "991--1000",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma

T2 - A target for cholangiocarcinoma treatment

AU - Thanee, Malinee

AU - Loilome, Watcharin

AU - Techasen, Anchalee

AU - Sugihara, Eiji

AU - Okazaki, Shogo

AU - Abe, Shinya

AU - Ueda, Shiho

AU - Masuko, Takashi

AU - Namwat, Nisana

AU - Khuntikeo, Narong

AU - Titapun, Attapol

AU - Pairojkul, Chawalit

AU - Saya, Hideyuki

AU - Yongvanit, Puangrat

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Expression of CD44, especially the variant isoforms (CD44v) of this major cancer stem cell marker, contributes to reactive oxygen species (ROS) defense through stabilizing xCT (a cystine–glutamate transporter) and promoting glutathione synthesis. This enhances cancer development and increases chemotherapy resistance. We investigate the role of CD44v in the regulation of the ROS defense system in cholangiocarcinoma (CCA). Immunohistochemical staining of CD44v and p38MAPK (a major ROS target) expression in Opisthorchis viverrini-induced hamster CCA tissues (at 60, 90, 120, and 180 days) reveals a decreased phospho-p38MAPK signal, whereas the CD44v signal was increased during bile duct transformation. Patients with CCA showed CD44v overexpression and negative-phospho-p38MAPK patients a significantly shorter survival rate than the low CD44v signal and positive-phospho-p38MAPK patients (P = 0.030). Knockdown of CD44 showed that xCT and glutathione levels were decreased, leading to a high level of ROS. We examined xCT-targeted CD44v cancer stem cell therapy using sulfasalazine. Glutathione decreased and ROS increased after the treatment, leading to inhibition of cell proliferation and induction of cell death. Thus, the accumulation of CD44v leads to the suppression of p38MAPK in transforming bile duct cells. The redox status regulation of CCA cells depends on the expression of CD44v to contribute the xCT function and is a link to the poor prognosis of patients. Thus, an xCT inhibitor could inhibit cell growth and activate cell death. This suggests that an xCT-targeting drug may improve CCA therapy by sensitization to the available drug (e.g. gemcitabine) by blocking the mechanism of the cell's ROS defensive system.

AB - Expression of CD44, especially the variant isoforms (CD44v) of this major cancer stem cell marker, contributes to reactive oxygen species (ROS) defense through stabilizing xCT (a cystine–glutamate transporter) and promoting glutathione synthesis. This enhances cancer development and increases chemotherapy resistance. We investigate the role of CD44v in the regulation of the ROS defense system in cholangiocarcinoma (CCA). Immunohistochemical staining of CD44v and p38MAPK (a major ROS target) expression in Opisthorchis viverrini-induced hamster CCA tissues (at 60, 90, 120, and 180 days) reveals a decreased phospho-p38MAPK signal, whereas the CD44v signal was increased during bile duct transformation. Patients with CCA showed CD44v overexpression and negative-phospho-p38MAPK patients a significantly shorter survival rate than the low CD44v signal and positive-phospho-p38MAPK patients (P = 0.030). Knockdown of CD44 showed that xCT and glutathione levels were decreased, leading to a high level of ROS. We examined xCT-targeted CD44v cancer stem cell therapy using sulfasalazine. Glutathione decreased and ROS increased after the treatment, leading to inhibition of cell proliferation and induction of cell death. Thus, the accumulation of CD44v leads to the suppression of p38MAPK in transforming bile duct cells. The redox status regulation of CCA cells depends on the expression of CD44v to contribute the xCT function and is a link to the poor prognosis of patients. Thus, an xCT inhibitor could inhibit cell growth and activate cell death. This suggests that an xCT-targeting drug may improve CCA therapy by sensitization to the available drug (e.g. gemcitabine) by blocking the mechanism of the cell's ROS defensive system.

KW - CD44v

KW - cholangiocarcinoma

KW - opisthorchiasis

KW - redox status

KW - sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=84978785922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978785922&partnerID=8YFLogxK

U2 - 10.1111/cas.12967

DO - 10.1111/cas.12967

M3 - Article

C2 - 27176078

AN - SCOPUS:84978785922

VL - 107

SP - 991

EP - 1000

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -